Drug Profile
AD 04 - Advantage Therapeutics
Alternative Names: AD04™; AD04™ - Advantage Therapeutics; Alhydrogel®Latest Information Update: 23 Jun 2023
Price :
$50
*
At a glance
- Originator AFFiRiS
- Developer ADvantage Therapeutics; AFFiRiS
- Class Antidementias
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Alzheimer's disease
Most Recent Events
- 20 Jun 2023 ADvantage Therapeutics receives Clinical Trial Application (CTA) approval to commence a phase IIb trial for Alzheimer’s disease in Poland, Bulgaria and Slovakia
- 02 May 2023 Phase-II clinical trials in Alzheimer's disease (Early-stage disease, In the elderly, In adults) in Bulgaria, Austria (SC) (EudraCT2022-003532-73)
- 02 May 2023 Phase-II clinical trials in Alzheimer's disease (Early-stage disease, In adults, In the elderly) in Slovakia (SC) (EudraCT2022-003532-73)